Fundraising Fox
ユナイテッド・イミュニティ株式会社
Founded 2017 · 17 employees on LinkedIn · 3 known investors
Find your way into ユナイテッド・イミュニティ株式会社
Sign up to find every way you can get introduced to ユナイテッド・イミュニティ株式会社
- Your email: who you already know at ユナイテッド・イミュニティ株式会社, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the ユナイテッド・イミュニティ株式会社 team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
United Immunity develops a myeloid-targeting platform using pullulan-based nanoparticles to selectively deliver therapeutic agents and vaccine antigens to macrophages and dendritic cells. The platform targets these immune cells through DC-SIGN receptor binding for cancer immunotherapy, vaccines, and treatment of fibrosis, viral infections, and inflammatory diseases.
Investors · 3
UTEClisted by UTECTokyo
How we know: UTEC's portfolio page · Not right? Tell us
.png){kind=logo}
Aozora Corporate InvestmentreportedTokyo
How we know: the VCSheet dataset · Not right? Tell us
Frequently asked questions
- What does ユナイテッド・イミュニティ株式会社 do?
- United Immunity develops a myeloid-targeting platform using pullulan-based nanoparticles to selectively deliver therapeutic agents and vaccine antigens to macrophages and dendritic cells. The platform targets these immune cells through DC-SIGN receptor binding for cancer immunotherapy, vaccines, and treatment of fibrosis, viral infections, and inflammatory diseases.
- Who are ユナイテッド・イミュニティ株式会社's investors?
- ユナイテッド・イミュニティ株式会社's investors include Nippon Venture Capital, UTEC, Aozora Corporate Investment.